hrp0094p2-426 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2021

Uterus agenesia in a patient with CATCH 22 Syndrome. Purpose of a case

Ignacio Diez-Lopez , Mesonero Saray , Maeso Sandra , Sarasua-Miranda Ainhoa

Introduction: The CATCH 22 syndrome or DiGeorge syndrome or velocardiofacial syndrome, is a frequent pathology with the worldwide prevalence estimated between 1 / 2,000 and 1 / 4,000 live births. The classic clinic is characterized by typical facial features (narrow palpebral fissures, bulbous nasal tip, small mouth and ears, malar hypoplasia) with functional insufficiency of the soft palate in about 75% of those affected, difficulties in learning, language and behavior , cong...

hrp0086p1-p639 | Growth P1 | ESPE2016

Spanish ECOS Study Analysis: Socioeconomic Data, Adherence and Growth Outcomes with Case Studies

Rodriguez-Arnao Maria , Sanchez Amparo Rodriguez , Lopez Ignacio Diez , Fernandez Joaquin Ramirez , de la Vega Jose Bermudez , Ballano Virginia , Nieto Jenny Alvarez , Koledova Ekaterina

Background: The ECOS observational study in Spain (NCT01376921) aims to evaluate adherence to r-hGH therapy prescribed via the easypod™ electromechanical auto-injector device and to analyse factors that may influence adherence in paediatric patients. Easypod™ administers pre-set doses of Saizen® r-hGH and stores accurate records of each dose and injection taken, which can then be shared with the HCP for evaluation of the patient’s adherence.<...

hrp0094p2-438 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2021

Congenital adrenal hyperplasia in detail: A multicentric and interdisciplinary study in minors with different sexual development

Ignacio Diez-Lopez , Nerea Gonzalez-Temprano , Villalon Flor , Larreina de la Fuente Leire , Cancela Vanesa , Nuñez Francisco Javier , Hernandez Jone Miren

Of the 67 included DSD patients, 33% were HSCs. 68% women and 32% men, with a total concordance between legal sex, current gender and chromosomal sex. Median age: 10.5 years, IQR 8-14. The most frequent clinical form was non-classical (NC) 45.5%, followed by classical with saline loss (CPS) 41%. The distribution of each clinical form according to the karyotype is significant (P = 0.013), the most frequent with XY karyotype is CPS and in NC forms all cases are XX. Med...

hrp0084p3-622 | Adrenals | ESPE2015

Prenatal Treatment of Congenital Adrenal Hyperplasia: A Survey of Paediatric Endocrinologist

Guindulain Maria J Chueca , Riano-Galan Isolina , Cardon Elisabeth Blarduni , Perez Ma Victoria Borras , Feijoo Lidia Castro , Lopez Ignacio Diez , Sanz Ma Angeles Donoso , Aromir Gertrudis Marti , Calvo Ma Teresa Munoz , Mercader Pilar Terradas

Background: Prenatal dexamethasone (DXM) treatment has been proposed to prevent genital virilization in girls with congenital adrenal hyperplasia (CAH), however its safety has been questioned for potential adverse effects on the foetus and the mother.Objective and hypotheses: To analyse clinical practice and prenatal treatment experience with DXM during pregnancy at risk of having her daughters with severe CAH.Method: An online sur...

hrp0094p2-461 | Thyroid | ESPE2021

Early reassessment in congenital hypothyroidism

Grau Gema , Bertholt María Laura , Chueca María , Artola Elena , Fernández María Concepción , Sarasua Ainhoa , Rodríguez Amaia , Vela Amaia , Berrade Sara , Naranjo Cristina , Puges Laura , Diez Ignacio , Espada Mercedes , Ascunce Nieves , Porras Begoña , Rica Itxaso

Introduction: 2020 ESPE guidelines recommend early reevaluation in primary congenital hypothyroidism (PCH) with thyroid in situ (TIS) and with levothyroxine dose lower than 3 mg/kg/day.Materials and Methods: Our Congenital Hypothyroidism screening program determine TSH and TT4 in dried blood spot (DBS) at 48 hours of life. A second DBS (DBS2) is indicated when the first is positive. Multicenter retrospective study (05/2016-05/2020; 105...

hrp0094p2-480 | Thyroid | ESPE2021

TBG deficiency and Central Congenital Hypothyroidism (CCH): Our experience in neonatal screening with TSH and T4

Chueca Maria J. , Grau Gema , Bertholt Laura , Artola Elena , Fernández Concepción , Sarasua Ainhoa , Rodriguez Amaia , Vela Amaia , Belza Amaia , Berrade Sara , Dura Teodoro , Alonso Pablo , Puges Laura , Diez Ignacio , Espada Mercedes , Ederra Maria , Ascunce Nieves , Porras Begoña , Rica Itxaso

Objective: Analyze CCH detection program results from 3 Autonomous Communities: TSH and total T4 (TT4) in dried blood spot (DBS) at initial screening (48 hours of life) and at retesting. Describe the characteristics of neonates with screening compatible with CCH. Consider whether TBG deficiency (TBGD) is an added difficulty in said study.Materials and Methods: Retrospective study (May 2016-May 2020) of all neonates ≥33 weeks and/or ≥1500 gr...